The next evolution of genomic testing is here. Today! Read the press release 🧬 Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0 👉 https://lnkd.in/es73ib_W If you're at #NSGC24, stop by Variantyx booth 426 to find out more about Genomic Unity 2.0 - the ultimate diagnostic test.
Variantyx
Biotechnology Research
Framingham, Massachusetts 12,816 followers
Variantyx is a technology-driven precision medicine company providing state-of-the-art genomic testing.
About us
Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.
- Website
-
https://www.variantyx.com
External link for Variantyx
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Framingham, Massachusetts
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Genomic diagnostics, Rare diseases, Whole genome sequencing, NGS data analysis, Clinical reporting, and Cancer predisposition
Locations
-
Primary
1671 Worcester Rd
Suite 300
Framingham, Massachusetts 01701-5400, US
-
75 Golomb St
Herzliya, IL
Employees at Variantyx
Updates
-
Thanks to the comprehensive analysis power of IriSight™ #wholegenome testing, we find that ~6% of prenatal cases result in a dual diagnosis. Download our latest prenatal case study to see how a mix of small sequence changes and single exon deletions was uniquely detected in a single test 👉 https://ow.ly/hLL450T8ZkR
-
3 out of 4 patients with inherited retinal degeneration are likely to receive a molecular diagnosis with #wholegenome testing. Only Genomic Unity® Retinal Disorders Analysis includes analysis of: ✔️ Nuclear and mitochondrial genes ✔️ Variants in GC-rich and regulatory regions ✔️ Copy number variants ✔️ ATXN7 repeat expansions All in a single test. Learn more 👉 https://ow.ly/Wvhc50SX266
-
#SpinalMuscularAtrophy impacts adolescents and adults too. For broad testing of motor neuron disorders including spinal muscular atrophy, #wholegenome testing with Genomic Unity® Motor Neuron Disorders Analysis provides comprehensive detection of SNVs/indels, CNVs, inversions, AR and C9orf72 repeat expansions - all in one test. Learn more 👉 https://ow.ly/JScS50SX1XI
-
Variantyx is thrilled to mark a decade of leading in whole genome testing. Over these 10 incredible years, we’ve found answers for our patients and forged meaningful relationships with our customers. A huge THANK YOU to our dedicated employees and loyal customers who’ve made this journey possible. Here’s to many more years of groundbreaking work and shared success! 🌟 #Variantyx #10YearsStrong #WholeGenomeSequncing #WGS #Wholegenomeanalysis
-
See how Genomic Unity® whole genome testing made a spastic ataxia diagnosis following multiple negative tests using other technologies. Click the link to watch the video 👉 https://ow.ly/GwNm50SCy6S
-
Did you know whole genome testing detects inversions? Download our case study featuring a Glass syndrome diagnosis made thanks to detection of an inversion affecting the SATB2 gene 👉 https://ow.ly/BaMu50SJy1s